– Advanced SURF301 Phase 1 oncology study; Initial Phase 1 results to be reported in 2H 2024 – – TYRA-300 Phase 2 ACH IND submission on track for 2H 2024 – – Initiated SURF201 Phase 1 study and dosed first patient with TYRA-200 – – Strengthened balance sheet with approximately $200 million PIPE in Q1 2024; pro-forma cash, cash equivalents, and marketable securities of approximately $403.5 million –
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
